Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...

The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca's TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malignant cells.

The government has identified life sciences as one of the sectors with the highest potential for growth in the UK and plans to make it a key pillar of its upcoming industry strategy. The ...

Thanks to the spending growth cap, the U.K. government in December 2024 announced that companies would need to pay a 22.9% ...

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI ...